Print Page  Close Window
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document

Slide 25

NUZYRA: Well Positioned for Blockbuster Potential Antibiotic Broad Spectrum Big 3(1) Indications Safety Oral Frequency 2010 Sales(3,4) Levofloxacin 3 Once Daily $3.4B Co-Amoxy clav 3 Twice Daily $2.8B Azithromycin(2) 2 Once Daily $1.8B Ciprofloxacin 3 Twice Daily $1.4B Clarithromycin(2) 2 Twice Daily $1.4B NUZYRA(5) 3 Once Daily N/A (1) Skin, Respiratory, UTI (2) Both Azithromycin and Clarithromycin did not have UTI claim (3) IMS global sales data in 2010 (4) Major patents had expired for all products by 2010 except Levofloxacin where 2010 was peak year sales (5) Anticipated based on current development plan >65% of Revenue was Generated by the Oral Formulations